Elutia (ELUT) Stock Price, News & Analysis

Company Overview

Elutia, Inc. is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions. Elutia’s platform may also have applications in acute respiratory distress and inflammatory diseases, and the company continues to explore partnerships to expand its pipeline and accelerate development timelines.

Founded in 2015 and headquartered in New Haven, Connecticut, Elutia serves the U.S. market and is pursuing collaborations to support international expansion. Its management team brings together expertise in biopharmaceutical research, clinical development, and regulatory affairs, with a shared focus on advancing innovative therapies toward regulatory approval and commercialization.

Key Stats

• Today's Range: $0.98 to $1.05
• 50-Day Range: $0.98 to $1.22
• 52-Week Range: $0.50 to $2.64
• Volume: 180,584 shs
• Average Volume: 97,468 shs
• Market Capitalization: $42.73 million
• P/E Ratio: 1.22
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Moderate Buy

Elutia Stock Analysis - MarketRank™

Elutia scored higher than 56% of companies evaluated by MarketBeat, and ranked 385th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Elutia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Elutia has a consensus price target of $6.00, representing about 500.7% upside from its current price of $1.00.

Amount of Analyst Coverage

Elutia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elutia is 1.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.44.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elutia is 1.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.56.

Price to Book Value per Share Ratio

Elutia has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.40% of the float of Elutia has been sold short.

Short Interest Ratio / Days to Cover

Elutia has a short interest ratio ("days to cover") of 1.71, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elutia has recently decreased by 2.81%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elutia does not currently pay a dividend.

Dividend Growth

Elutia does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

5 people have added Elutia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elutia insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.60% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELUT Stock Analysis - Frequently Asked Questions

How have ELUT shares performed this year?

Elutia's stock was trading at $0.6927 at the beginning of the year. Since then, ELUT stock has increased by 44.2% and is now trading at $0.9988.

How were Elutia's earnings last quarter?

Elutia Inc. (NASDAQ:ELUT) posted its quarterly earnings results on Wednesday, March, 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). The business had revenue of $3.30 million for the quarter, compared to analysts' expectations of $3.30 million.
Read the conference call transcript.

When did Elutia IPO?

Elutia (ELUT) raised $50 million in an IPO on Wednesday, October 7th 2020. The company issued 2,941,176 shares at a price of $16.00-$18.00 per share.

Who are Elutia's major shareholders?

Top institutional investors of Elutia include AIGH Capital Management LLC (8.40%), Perkins Capital Management Inc. (1.77%) and Rossmore Private Capital (0.28%). Insiders that own company stock include Highcape Capital, LP, Matthew Ferguson, C Randal Mills, David Colpman and Brigid Makes.
View institutional ownership trends.

How do I buy shares of Elutia?

Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Elutia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elutia investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL), Meta Platforms (META) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 3/11/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELUT
• CIK: 1708527
• Web: www.elutia.com
• Phone: 240-247-1170
• Fax: 510-307-9896
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Elutia: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +500.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.82
• Trailing P/E Ratio: 1.22
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $53.38 million
• Net Margins: 282.63%
• Pretax Margin: -129.00%
• Return on Equity: N/A
• Return on Assets: -49.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.22
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $12.29 million
• Price / Sales: 3.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.65 per share
• Price / Book: 1.54

Miscellaneous

• Outstanding Shares: 42,780,000
• Free Float: 30,976,000
• Market Cap: $42.73 million
• Optionable: Not Optionable
• Beta: 0.75